Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology.
José Cleberson Santos SoaresIago Dillion Lima CavalcantiJuliana Lúcia de Albuquerque VasconcelosPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
As they are large and complex molecules, it is impossible to obtain identical copies of their reference products, which generates conflicts and concerns on the part of the pharmaceutical class regarding the safety in the interchangeability of these products, highlighting the importance of pharmacovigilance in this process.